multiple myeloma

Kerri FitzgeraldMyeloma | November 16, 2022

This triplet combination is safe and effective in patients with relapsed/refractory multiple myeloma...

Leah SherwoodMyeloma | November 16, 2022

CART-ddBCMA demonstrated a 100% overall response rate in patients with relapsed/refractory multiple myeloma.

Leah SherwoodMeeting News | November 22, 2022

Patients with both multiple myeloma (MM) and secondary immunodeficiencies (SID) face...

Leah SherwoodMeeting News | November 22, 2022

Adding a monoclonal antibody to a triplet treatment significantly lowered the risk of disease...

Leah SherwoodMyeloma | November 16, 2022

The data were from the phase III DETERMINATION trial...

Cecilia BrownMeeting News | November 22, 2022

Adding ixazomib to pomalidomide and dexamethasone improved progression-free survival rates...

Cecilia BrownPrint | February 1, 2023

The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies.

Leah SherwoodMyeloma | November 16, 2022

The European Commission (EC) has granted marketing authorization for selinexor, an oral exportin 1 inhibitor...

Leah SherwoodMyeloma | November 22, 2022

The EMA’s CHMP recommendation is based on positive results from the multicohort, open-label...

Cecilia BrownMyeloma | November 22, 2022

The benefit of maintenance therapy with ixazomib after allogenic hematopoietic stem cell transplantation...

In patients with newly diagnosed MM, the addition of AHSCT to a triplet regimen of lenalidomide, bortezomib, and ...

Kerri FitzgeraldAcute Myeloid Leukemia | November 16, 2022

The FDA has cleared the IND application for LAVA-051, humanized Gammabody designed to activate...

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer